Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.

Deerfield partner Jonathan Leff issued a serious warning to the biotech industry during a policy panel at the BIO CEO & Investor Conference Feb. 14, declaring that sweeping changes to FDA’s drug approval standards under a new administration and a new commissioner could have “disastrous consequences” for biotech investment.

“FDA as we know it has been about regulating the efficacy as well as the safety of drugs,” Leff said....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip